Boston Scientific Corporation (NYSE: BSX) is one of 83 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare Boston Scientific Corporation to similar companies based on the strength of its institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Boston Scientific Corporation and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific Corporation 0 4 13 0 2.76
Boston Scientific Corporation Competitors 267 1850 3312 105 2.59

Boston Scientific Corporation currently has a consensus price target of $31.11, suggesting a potential upside of 10.54%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.06%. Given Boston Scientific Corporation’s stronger consensus rating and higher possible upside, research analysts clearly believe Boston Scientific Corporation is more favorable than its peers.

Earnings & Valuation

This table compares Boston Scientific Corporation and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Boston Scientific Corporation $8.71 billion $2.31 billion 46.13
Boston Scientific Corporation Competitors $2.06 billion $438.96 million -76.08

Boston Scientific Corporation has higher revenue and earnings than its peers. Boston Scientific Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

90.5% of Boston Scientific Corporation shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 0.7% of Boston Scientific Corporation shares are owned by company insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Boston Scientific Corporation has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Boston Scientific Corporation’s peers have a beta of 0.90, suggesting that their average stock price is 10% less volatile than the S&P 500.

Profitability

This table compares Boston Scientific Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Boston Scientific Corporation 9.55% 23.60% 9.24%
Boston Scientific Corporation Competitors -328.39% -35.89% -12.62%

Summary

Boston Scientific Corporation beats its peers on 11 of the 13 factors compared.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.